OraSure Technologies (Nasdaq:OSUR) announced that it has entered into an agreement with AbbVie to co-promote the Company’s OraQuick® HCV Rapid Test. The product will be used to test individuals at-risk for hepatitis C (HCV). “We believe it is critical that at-risk individuals be tested for hepatitis C to prevent serious consequences from untreated infection,” said Douglas A. Michels, President and CEO of OraSure. “This new collaboration allows us to educate healthcare professionals and the patients they treat about hepatitis C and provide them with a very important rapid diagnostic tool.” Read more http://bit.ly/1snZJaO
Client & Alumni News
OraSure Technologies Announces New Co-Promotion Agreement for OraQuick HCV Rapid Antibody Test
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.